Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, and Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, and Others), Route of Administration (Intravenous, Oral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others) – Industry Trends and Forecast to 2031.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Size
In the dynamic Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, ongoing research explores innovative treatments. A promising new method showcases potential advancements, offering hope for improved outcomes. These developments signify a transformative era in CIDP management, fostering optimism for patients and healthcare stakeholders alike.
Data Bridge Market Research analyses that the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market which was USD 1.74 billion in 2023, is expected to reach USD 3.11 billion by 2031, and is expected to undergo a CAGR of 7.50% during the forecast period of 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, and Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, and Others), Route of Administration (Intravenous, Oral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), and Actelion Pharmaceuticals Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
CIDP is a neurological disorder causing chronic inflammation and damage to peripheral nerves, resulting in weakness, numbness, and impaired motor function. It is characterized by progressive demyelination of nerve fibers, leading to impaired nerve signal transmission. Treatment typically involves immunosuppressive therapy to manage symptoms and prevent further nerve damage.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics
Drivers
- Increasing Prevalence of CIDP
The global rise in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) prevalence is strengthened by increased awareness and enhanced diagnostic capabilities. This trend drives greater identification of cases, consequently escalating the demand for CIDP treatments. As understanding of the condition expands, the need for effective therapeutic interventions becomes increasingly pronounced, propelling market growth.
- Regulatory Support for Therapy Approvals
Regulatory agencies acknowledge CIDP's severity, expediting therapy approvals and stimulating R&D investment. This recognition fosters innovation, enhancing treatment options and patient outcomes. Consequently, pharmaceutical companies are incentivized to develop novel therapies, driving progress in CIDP management and expanding the market for effective treatments.
Opportunities
- Technological Advancements in Diagnosis
Advancements in CIDP diagnosis, driven by an improved understanding of its pathophysiology and diagnostic technologies, enable earlier and more accurate identification of patients. This expands the pool eligible for treatment, facilitating timely intervention and improving patient outcomes. Early diagnosis also supports research efforts and enhances healthcare strategies for managing CIDP effectively.
- Rising Demand for Emerging Therapies
The CIDP treatment pipeline is diversifying with innovative approaches such as monoclonal antibodies, gene therapies, and small molecules. These promising treatments provide alternative options for patients, fostering market growth by addressing unmet medical needs and driving research and development in the quest for more effective therapies.
Restraints/Challenges
- Chances for Relapse and Disease Progression
Despite treatment, CIDP patients may suffer relapses or worsening neurological function. Managing these fluctuations is challenging, often requiring treatment adjustments. The unpredictable nature of disease progression necessitates ongoing monitoring and personalized care to optimize outcomes and mitigate the impact on patients quality of life.
- High Cost of Treatment
The high cost of CIDP treatments such as IVIG therapy and immunosuppressants presents a significant barrier to access, especially in regions with limited healthcare coverage or high out-of-pocket expenses. Affordability challenges may hinder patients' ability to receive necessary care, impacting their quality of life and exacerbating health disparities within affected populations.
This global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2022, Bio Products Laboratory (BPL), headquartered in Elstree, U.K., obtained marketing authorization for Coagadex in the Dominican Republic, marking a milestone in CIDP treatment. Coagadex, the first therapy for Hereditary Factor X Deficiency, promises advancements in addressing similar rare neurological conditions
- In February 2022, Grifols initiated a partnership with Endpoint Health, Inc. to develop an Antithrombin III (AT-III) therapy for treating Sepsis, presenting potential implications for CIDP management. This collaboration underscores efforts to explore therapeutic avenues applicable to immune-mediated neuropathies including CIDP
- In January 2022, Janssen Pharmaceutica forged a collaboration with SRI International to leverage SRI's SynFin platform in small molecule drug discovery, offering prospects for CIDP research. The agreement signifies a step towards utilizing innovative AI-guided approaches to address complex neurological disorders such as CIDP
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Scope
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is segmented on the basis of treatment, diagnosis, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Intravenous Immunoglobulin
- Corticosteroids
- Plasmapheresis
- Physiotherapy
- Others
Diagnosis
- Electrodiagnostic Testing
- Nerve Conduction
- EMG
- Spinal Fluid Analysis
- Others
Route of Administration
- Intravenous
- Oral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional Analysis/Insights
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is analyzed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-user, and distribution channel as referenced above.
The countries covered in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
Asia-Pacific is expected to dominate the market, driven by increased research and development of plasma-derived medicines. Government support, through awareness programs and drug approvals, further fuels growth in this region, shaping the landscape of CIDP treatment.
North America is considered to have the highest lucrative growth in the market due to the high-income of the countries and favorable reimbursement, propelling advancements in treatment accessibility and research.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global chronic inflammatory demyelinating polyneuropathy (CIDP) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share Analysis
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Actelion Pharmaceuticals Ltd (Switzerland)
SKU-